Immunotherapy has revolutionized the field of oncology by utilizing the body's immune system to fight cancer. This article aims to provide physicians with an in-depth understanding of this groundbreaking treatment modality.
Immunotherapy works by enhancing the immune response against cancer cells. It includes a range of treatment options such as immune checkpoint inhibitors, cancer vaccines, and adoptive cell transfer. These therapies can be used alone or in combination with other treatments to increase their effectiveness.
Immune checkpoint inhibitors are drugs that block immune checkpoints. These checkpoints are proteins that prevent immune cells from attacking normal cells in the body. By blocking these checkpoints, the drugs allow immune cells to respond more strongly to cancer. Key checkpoint inhibitors include PD-1/PD-L1 inhibitors and CTLA-4 inhibitors.
Cancer vaccines, unlike traditional vaccines, are usually given after a cancer diagnosis to stimulate the immune system to attack cancer cells. These vaccines can be specific to a type of cancer or customized to an individual patient's cancer.
Adoptive cell transfer involves modifying a patient's immune cells to enhance their ability to fight cancer. CAR-T cell therapy, a form of adoptive cell transfer, has shown promising results in treating certain types of leukemia and lymphoma.
While immunotherapy has proven effective, it's not suitable for every patient. Physicians must consider factors like the type and stage of cancer, patient health, and previous treatments. Side effects can range from mild to severe and may include fatigue, pain, and immune-related adverse events.
Immunotherapy is a powerful tool in the fight against cancer. As our understanding of the immune system and cancer biology continues to grow, so too will the potential of immunotherapy. It's crucial for physicians to stay updated on this rapidly evolving field to provide the best possible care for their patients.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation